Gender representation in trials

Curtis L Meinert, Adele Kaplan Gilpin, Aynur Ünalp, Christopher Dawson

Research output: Contribution to journalArticle

Abstract

The perception is that women have been understudied relative to men. It has been sufficient to cause Congress to enact legislation to require that a clinical trial must be 'designed and carried out in a manner sufficient to provide for a valid analysis of whether the variables being studied in the trial affect women ... differently than other subjects in the trial.' We looked for evidence as to whether the perception has a basis in fact by looking at measures of gender-based research effort. Clinical trials, published between 1966 and 1998 in U.S. journals and indexed in MEDLINE, were classified by gender. Reports of trials (n = 724) appearing in five widely circulated medical journals (Annals of Internal Medicine, British Medical Journal, Journal of the American Medical Association, Lancet, and New England Journal of Medicine) in 1985, 1990, and 1995 were retrieved and read to obtain counts of the numbers of males and females represented in trials published in those journals. For reports of trials published in U.S. journals (n = 100,455), the percent involving males and females, males only, females only, and those where gender was not specified were 55.2%, 12.2%, 11.2%, and 21.4%, respectively. Counts of males and females represented in the reports of trials appearing in the five aforementioned journals were 355,624 and 550,743, respectively. We did not find evidence of systematic effort bias against females. Control Clin Trials 2000;21:462-475 Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)462-475
Number of pages14
JournalControlled Clinical Trials
Volume21
Issue number5
DOIs
StatePublished - Oct 2000

Fingerprint

Clinical Trials
New England
American Medical Association
Internal Medicine
Legislation
MEDLINE
Medicine
Research

Keywords

  • Bias
  • Clinical research
  • Clinical trials
  • Gender
  • Legislation
  • Women's health

ASJC Scopus subject areas

  • Pharmacology

Cite this

Gender representation in trials. / Meinert, Curtis L; Gilpin, Adele Kaplan; Ünalp, Aynur; Dawson, Christopher.

In: Controlled Clinical Trials, Vol. 21, No. 5, 10.2000, p. 462-475.

Research output: Contribution to journalArticle

Meinert, CL, Gilpin, AK, Ünalp, A & Dawson, C 2000, 'Gender representation in trials', Controlled Clinical Trials, vol. 21, no. 5, pp. 462-475. https://doi.org/10.1016/S0197-2456(00)00086-6
Meinert, Curtis L ; Gilpin, Adele Kaplan ; Ünalp, Aynur ; Dawson, Christopher. / Gender representation in trials. In: Controlled Clinical Trials. 2000 ; Vol. 21, No. 5. pp. 462-475.
@article{a0b640346ec54b7282e8fa8485db3f96,
title = "Gender representation in trials",
abstract = "The perception is that women have been understudied relative to men. It has been sufficient to cause Congress to enact legislation to require that a clinical trial must be 'designed and carried out in a manner sufficient to provide for a valid analysis of whether the variables being studied in the trial affect women ... differently than other subjects in the trial.' We looked for evidence as to whether the perception has a basis in fact by looking at measures of gender-based research effort. Clinical trials, published between 1966 and 1998 in U.S. journals and indexed in MEDLINE, were classified by gender. Reports of trials (n = 724) appearing in five widely circulated medical journals (Annals of Internal Medicine, British Medical Journal, Journal of the American Medical Association, Lancet, and New England Journal of Medicine) in 1985, 1990, and 1995 were retrieved and read to obtain counts of the numbers of males and females represented in trials published in those journals. For reports of trials published in U.S. journals (n = 100,455), the percent involving males and females, males only, females only, and those where gender was not specified were 55.2{\%}, 12.2{\%}, 11.2{\%}, and 21.4{\%}, respectively. Counts of males and females represented in the reports of trials appearing in the five aforementioned journals were 355,624 and 550,743, respectively. We did not find evidence of systematic effort bias against females. Control Clin Trials 2000;21:462-475 Copyright (C) 2000 Elsevier Science Inc.",
keywords = "Bias, Clinical research, Clinical trials, Gender, Legislation, Women's health",
author = "Meinert, {Curtis L} and Gilpin, {Adele Kaplan} and Aynur {\"U}nalp and Christopher Dawson",
year = "2000",
month = "10",
doi = "10.1016/S0197-2456(00)00086-6",
language = "English (US)",
volume = "21",
pages = "462--475",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Gender representation in trials

AU - Meinert, Curtis L

AU - Gilpin, Adele Kaplan

AU - Ünalp, Aynur

AU - Dawson, Christopher

PY - 2000/10

Y1 - 2000/10

N2 - The perception is that women have been understudied relative to men. It has been sufficient to cause Congress to enact legislation to require that a clinical trial must be 'designed and carried out in a manner sufficient to provide for a valid analysis of whether the variables being studied in the trial affect women ... differently than other subjects in the trial.' We looked for evidence as to whether the perception has a basis in fact by looking at measures of gender-based research effort. Clinical trials, published between 1966 and 1998 in U.S. journals and indexed in MEDLINE, were classified by gender. Reports of trials (n = 724) appearing in five widely circulated medical journals (Annals of Internal Medicine, British Medical Journal, Journal of the American Medical Association, Lancet, and New England Journal of Medicine) in 1985, 1990, and 1995 were retrieved and read to obtain counts of the numbers of males and females represented in trials published in those journals. For reports of trials published in U.S. journals (n = 100,455), the percent involving males and females, males only, females only, and those where gender was not specified were 55.2%, 12.2%, 11.2%, and 21.4%, respectively. Counts of males and females represented in the reports of trials appearing in the five aforementioned journals were 355,624 and 550,743, respectively. We did not find evidence of systematic effort bias against females. Control Clin Trials 2000;21:462-475 Copyright (C) 2000 Elsevier Science Inc.

AB - The perception is that women have been understudied relative to men. It has been sufficient to cause Congress to enact legislation to require that a clinical trial must be 'designed and carried out in a manner sufficient to provide for a valid analysis of whether the variables being studied in the trial affect women ... differently than other subjects in the trial.' We looked for evidence as to whether the perception has a basis in fact by looking at measures of gender-based research effort. Clinical trials, published between 1966 and 1998 in U.S. journals and indexed in MEDLINE, were classified by gender. Reports of trials (n = 724) appearing in five widely circulated medical journals (Annals of Internal Medicine, British Medical Journal, Journal of the American Medical Association, Lancet, and New England Journal of Medicine) in 1985, 1990, and 1995 were retrieved and read to obtain counts of the numbers of males and females represented in trials published in those journals. For reports of trials published in U.S. journals (n = 100,455), the percent involving males and females, males only, females only, and those where gender was not specified were 55.2%, 12.2%, 11.2%, and 21.4%, respectively. Counts of males and females represented in the reports of trials appearing in the five aforementioned journals were 355,624 and 550,743, respectively. We did not find evidence of systematic effort bias against females. Control Clin Trials 2000;21:462-475 Copyright (C) 2000 Elsevier Science Inc.

KW - Bias

KW - Clinical research

KW - Clinical trials

KW - Gender

KW - Legislation

KW - Women's health

UR - http://www.scopus.com/inward/record.url?scp=0033833111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033833111&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(00)00086-6

DO - 10.1016/S0197-2456(00)00086-6

M3 - Article

VL - 21

SP - 462

EP - 475

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 5

ER -